Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Clinical trial NCT05633602 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05633602
Sponsor: SWOG Cancer Research Network
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Start date: 2023-03-14
Primary completion: 2025-11-26
Enrollment: 838

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.